News | Catheters | April 21, 2022

MIVI Neuroscience Launches Largest Study Yet of its Aspiration Catheter for Thrombus Removal

The AQUAS Registry is a prospective registry of 250 subjects conducted across up to 12 high-volume, comprehensive stroke centers in Europe.

MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today announced the first patient enrollments in a multicenter clinical study to assess the safety and performance of the Q Aspiration Catheter used in a combined aspiration with stent-retriever technique for thrombus removal in patients who have suffered an acute ischemic stroke.  

Q Aspiration Catheter


April 21, 2022 – MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today announced the first patient enrollments in a multicenter clinical study to assess the safety and performance of the Q Aspiration Catheter used in a combined aspiration with stent-retriever technique for thrombus removal in patients who have suffered an acute ischemic stroke.   

The AQUAS Registry is a prospective registry of 250 subjects conducted across up to 12 high-volume, comprehensive stroke centers in Europe. It is the largest study of a MIVI device to date.  The study is expected to conclude within 12 months.

In the United States, approximately 50% of ischemic stroke interventions employ a combined technique; the other 50% use only an aspiration catheter. “In both cases, we want the physician to reach for the Q Aspiration Catheter because it offers the highest aspiration power available and a simpler setup,” said Bob Colloton, CEO of MIVI Neuroscience. “This registry is a massive undertaking, involving a large group of stroke experts, patients, and two important partners: study organizer Angionautix and Acandis, manufacturer of the stent retriever that will be used with our catheter. We believe that the Q Aspiration Catheter is the physician’s best choice, and the AQUAS Registry will provide us with additional data on its safety and performance.”

Led by Dr. Sebastian Remollo Friedemann of Hospital Universitari Germans Trias I Pujol in Barcelona, the registry will assess the safety and performance of the Q Aspiration Catheter combined with the Acandis Aperio stent-retriever in treating ischemic stroke patients.  

“The Q Aspiration Catheter is a powerful solution for stroke treatment,” said Dr. Remollo.  “I’m looking forward to solid evidence from the study that adds to my personal experience with the product and advancing the approach to thrombus removal.”

The Q Aspiration Catheter is CE-marked in Europe and under Investigational Device Exemption in the United States. 

For more information: www.mivineuro.com


Related Content

News | Cardiovascular Clinical Studies

September 19, 2023 — A mathematical and computational model of the human heart entirely developed at Politecnico di ...

Home September 19, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of ...

Home September 14, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing ...

Home September 08, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Patients of African ancestry with dilated cardiomyopathy (DCM) are less likely to have clinically ...

Home September 08, 2023
Home
Subscribe Now